Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm
- Conditions
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Target Recruit Count
- 100
- Registration Number
- NCT02675205
- Locations
- 🇫🇷
Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 20
- Registration Number
- NCT02663713
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece
The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02658838
- Locations
- 🇨🇳
Beijing Anzhen Hosipital, Beijing, Beijing, China
Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2021-08-23
- Target Recruit Count
- 50
- Registration Number
- NCT02639143
Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 260
- Registration Number
- NCT02627521
- Locations
- 🇨🇦
St. Michael's hospital, Toronto, Ontario, Canada
Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- University of Luebeck
- Target Recruit Count
- 138
- Registration Number
- NCT02627950
- Locations
- 🇩🇪
University of Luebeck, Luebeck, Germany
The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Baylor College of Medicine
- Registration Number
- NCT02626169
- Locations
- 🇺🇸
Baylor Clinic, Houston, Texas, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Comparing Ticagrelor Versus Clopidogrel on Microcirculation
- Conditions
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Dong-A University
- Target Recruit Count
- 120
- Registration Number
- NCT02618733
- Locations
- 🇰🇷
Department of Internal Medicine,Dong-A University College of Medicine, Busan, Korea, Republic of
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1900
- Registration Number
- NCT02617290
- Locations
- 🇫🇷
Institut de Cardiologie - USIC - Hôpital Pitié-Salpêtrière, Paris, France
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02612480
- Locations
- 🇳🇱
Intensive Care Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.